Cargando…
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necessary to understand how prior infection plus vaccina...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835846/ https://www.ncbi.nlm.nih.gov/pubmed/34376569 http://dx.doi.org/10.1126/scitranslmed.abj0847 |
_version_ | 1784868750973992960 |
---|---|
author | Urbanowicz, Richard A. Tsoleridis, Theocharis Jackson, Hannah J. Cusin, Lola Duncan, Joshua D. Chappell, Joseph G. Tarr, Alexander W. Nightingale, Jessica Norrish, Alan R. Ikram, Adeel Marson, Ben Craxford, Simon J. Kelly, Anthony Aithal, Guruprasad P. Vijay, Amrita Tighe, Patrick J. Ball, Jonathan K. Valdes, Ana M. Ollivere, Benjamin J. |
author_facet | Urbanowicz, Richard A. Tsoleridis, Theocharis Jackson, Hannah J. Cusin, Lola Duncan, Joshua D. Chappell, Joseph G. Tarr, Alexander W. Nightingale, Jessica Norrish, Alan R. Ikram, Adeel Marson, Ben Craxford, Simon J. Kelly, Anthony Aithal, Guruprasad P. Vijay, Amrita Tighe, Patrick J. Ball, Jonathan K. Valdes, Ana M. Ollivere, Benjamin J. |
author_sort | Urbanowicz, Richard A. |
collection | PubMed |
description | Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necessary to understand how prior infection plus vaccination can modulate immune responses against variants of concern. To address this, we sampled 20 individuals with and 25 individuals without confirmed previous SARS-CoV-2 infection from a large cohort of health care workers followed serologically since April 2020. All 45 individuals had received two doses of the Pfizer-BioNTech BNT162b2 vaccine with a delayed booster at 10 weeks. Absolute and neutralizing antibody titers against wild-type SARS-CoV-2 and variants were measured using enzyme immunoassays and pseudotype neutralization assays. We observed antibody reactivity against lineage A, B.1.351, and P.1 variants with increasing antigenic exposure, through either vaccination or natural infection. This improvement was further confirmed in neutralization assays using fixed dilutions of serum samples. The impact of antigenic exposure was more evident in enzyme immunoassays measuring SARS-CoV-2 spike protein–specific IgG antibody concentrations. Our data show that multiple exposures to SARS-CoV-2 spike protein in the context of a delayed booster expand the neutralizing breadth of the antibody response to neutralization-resistant SARS-CoV-2 variants. This suggests that additional vaccine boosts may be beneficial in improving immune responses against future SARS-CoV-2 variants of concern. |
format | Online Article Text |
id | pubmed-9835846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98358462023-01-13 Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection Urbanowicz, Richard A. Tsoleridis, Theocharis Jackson, Hannah J. Cusin, Lola Duncan, Joshua D. Chappell, Joseph G. Tarr, Alexander W. Nightingale, Jessica Norrish, Alan R. Ikram, Adeel Marson, Ben Craxford, Simon J. Kelly, Anthony Aithal, Guruprasad P. Vijay, Amrita Tighe, Patrick J. Ball, Jonathan K. Valdes, Ana M. Ollivere, Benjamin J. Sci Transl Med Reports Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necessary to understand how prior infection plus vaccination can modulate immune responses against variants of concern. To address this, we sampled 20 individuals with and 25 individuals without confirmed previous SARS-CoV-2 infection from a large cohort of health care workers followed serologically since April 2020. All 45 individuals had received two doses of the Pfizer-BioNTech BNT162b2 vaccine with a delayed booster at 10 weeks. Absolute and neutralizing antibody titers against wild-type SARS-CoV-2 and variants were measured using enzyme immunoassays and pseudotype neutralization assays. We observed antibody reactivity against lineage A, B.1.351, and P.1 variants with increasing antigenic exposure, through either vaccination or natural infection. This improvement was further confirmed in neutralization assays using fixed dilutions of serum samples. The impact of antigenic exposure was more evident in enzyme immunoassays measuring SARS-CoV-2 spike protein–specific IgG antibody concentrations. Our data show that multiple exposures to SARS-CoV-2 spike protein in the context of a delayed booster expand the neutralizing breadth of the antibody response to neutralization-resistant SARS-CoV-2 variants. This suggests that additional vaccine boosts may be beneficial in improving immune responses against future SARS-CoV-2 variants of concern. American Association for the Advancement of Science 2021-09-01 2021-08-10 /pmc/articles/PMC9835846/ /pubmed/34376569 http://dx.doi.org/10.1126/scitranslmed.abj0847 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reports Urbanowicz, Richard A. Tsoleridis, Theocharis Jackson, Hannah J. Cusin, Lola Duncan, Joshua D. Chappell, Joseph G. Tarr, Alexander W. Nightingale, Jessica Norrish, Alan R. Ikram, Adeel Marson, Ben Craxford, Simon J. Kelly, Anthony Aithal, Guruprasad P. Vijay, Amrita Tighe, Patrick J. Ball, Jonathan K. Valdes, Ana M. Ollivere, Benjamin J. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title_full | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title_fullStr | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title_full_unstemmed | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title_short | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection |
title_sort | two doses of the sars-cov-2 bnt162b2 vaccine enhance antibody responses to variants in individuals with prior sars-cov-2 infection |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835846/ https://www.ncbi.nlm.nih.gov/pubmed/34376569 http://dx.doi.org/10.1126/scitranslmed.abj0847 |
work_keys_str_mv | AT urbanowiczricharda twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT tsoleridistheocharis twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT jacksonhannahj twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT cusinlola twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT duncanjoshuad twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT chappelljosephg twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT tarralexanderw twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT nightingalejessica twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT norrishalanr twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT ikramadeel twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT marsonben twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT craxfordsimonj twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT kellyanthony twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT aithalguruprasadp twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT vijayamrita twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT tighepatrickj twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT balljonathank twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT valdesanam twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection AT olliverebenjaminj twodosesofthesarscov2bnt162b2vaccineenhanceantibodyresponsestovariantsinindividualswithpriorsarscov2infection |